Tissue Chips: Advancing Biomedical Research through Micro physiological Systems

James Robert^*
*Correspondence: James Robert, Department of Oncological Sciences, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, USA, Email:

Keywords

Tissue chips • Organs-on-chips • Micro physiological systems • Biomedical research

Introduction

Tissue chips have emerged as a groundbreaking technology in the field of biomedical research. Traditional cell cultures and animal models have limitations in accurately replicating human physiology, leading to challenges in translating research findings into clinical applications. Tissue chips offer a solution by providing physiologically relevant systems that better mimic human organs and their interactions within the body. The development of tissue chips involves integrating multiple disciplines, including biology, engineering, and materials science. These platforms consist of microfabricated chambers or channels that house living cells arranged in a manner that mimics the architecture of specific organs. Microfluidic systems control the flow of media and nutrients, allowing researchers to recreate the dynamic microenvironment necessary for organ function [1].

Tissue chips replicate the intricate structures and functions of human organs, enabling studies that closely mimic human physiology. Multiple tissue chips can be cultured simultaneously, allowing researchers to study various conditions and treatments in parallel. Tissue chips provide a more ethical and cost-effective alternative to traditional animal models, reducing the reliance on animal testing in preclinical research. Tissue chips hold promise for personalized medicine by enabling the testing of individual patient cells or tissues, leading to more targeted and effective treatments. Tissue chips can be used to model a wide range of diseases, including cancer, heart disease, liver disease, and neurological disorders. By recreating the diseased organ's microenvironment, researchers gain insights into disease mechanisms and potential therapeutic targets. Tissue chips allow for more accurate and efficient screening of potential drug candidates. They provide a platform to assess drug efficacy, toxicity, and metabolism in a human-specific context, thereby improving the drug development pipeline [2].

Literature Review

Tissue chips can assess the effects of environmental toxins on human organs, enabling better understanding of their impact and aiding in the development of safety regulations. Tissue chips hold promise for personalized medicine by allowing researchers to test different treatment approaches on a patient's own cells or tissues, leading to tailored therapeutic interventions. Developing tissue chips with the desired complexity to accurately mimic human organs is a technical challenge. There is a need for standardization and validation protocols to ensure reproducibility and comparability of results across different tissue chip platforms. Maintaining the viability and functionality of tissue chips over extended periods remains a challenge. The development of multi-organ systems, which mimic the interactions between different organs in the human body, is a complex task that requires further research [3].

As tissue chips move closer to clinical applications, regulatory considerations come into play. Regulatory agencies, such as the U.S. Food and Drug Administration (FDA), are actively engaging in discussions regarding the use of tissue chips in drug development and safety assessments. Establishing guidelines and standards for the validation, qualification, and regulatory acceptance of tissue chips will be essential to ensure their effective integration into the drug development process. The public's perception and acceptance of tissue chips will play a significant role in their widespread adoption. Educating the public about the benefits and potential applications of tissue chips, as well as addressing any concerns or misconceptions, is crucial for fostering trust and acceptance. Open dialogue and engagement with the public, along with transparent communication about the limitations and future prospects of tissue chips, can help shape a positive perception of this technology [4].

Discussion

Tissue chips should not be viewed as replacements for traditional research methods but rather as complementary tools. Integration with other research approaches, such as in vitro studies, animal models, and clinical trials, can provide a more comprehensive understanding of human physiology and disease. Collaborative efforts between researchers utilizing different methodologies can lead to synergistic advancements in biomedical research. The economic implications of tissue chips should also be taken into account. While tissue chips offer the potential for cost savings in drug development by providing more accurate predictions of human responses, there are initial investment costs associated with their development and implementation. Collaborations between academia, industry, and government funding agencies are essential to support the continued development and affordability of tissue chips [5].

Tissue chips have the potential to revolutionize biomedical research not only in developed countries but also in resource-limited settings. These platforms can facilitate research in areas with limited access to advanced laboratory facilities and animal models. The portability, scalability, and cost-effectiveness of tissue chips make them a valuable tool for global health research, enabling studies on diseases prevalent in specific regions and populations. The integration of tissue chips in drug development has the potential to enhance public health and drug safety. By providing more accurate predictions of drug efficacy and toxicity in human systems, tissue chips can help reduce the risk of adverse drug reactions and improve patient outcomes. This technology has the potential to revolutionize the pharmaceutical industry by enabling the development of safer and more effective drugs [6].

Conclusion

Tissue chips represent a transformative technology that bridges the gap between traditional in vitro models and human clinical trials. These microphysiological systems hold immense potential for advancing our understanding of human biology, disease mechanisms, and therapeutic interventions. With ongoing research, technological advancements, and collaborative efforts, tissue chips are poised to reshape biomedical research, drug development, and personalized medicine, ultimately improving healthcare outcomes for patients worldwide.

Acknowledgement

None.

Conflict of Interest

None.

References

1. Ashammakhi, Nureddin, Katherine Wesseling-Perry, Anwarul Hasan and Elmahdi Elkhammas, et al. "Kidney-on-a-chip: Untapped opportunities." Kidney Int 94 (2018): 1073-1086.

Google Scholar, Crossref, Indexed at

2. Bi, Hongyan, Sheng Meng, Yan Li and Kai Guo, et al. "Deposition of PEG onto PMMA microchannel surface to minimize nonspecific adsorption." Lab Chip 6 (2006): 769-775.

Google Scholar, Crossref, Indexed at

3. Campisi, Marco, Yoojin Shin, Tatsuya Osaki and Cynthia Hajal, et al. "3D self-organized microvascular model of the human blood-brain barrier with endothelial cells, pericytes and astrocytes." Biomater 180 (2018): 117-129.

Google Scholar, Crossref, Indexed at

4. Chen, Yupeng and Thomas J. Webster. "Increased osteoblast functions in the presence of BMP‐7 short peptides for nanostructured biomaterial applications." Japan Soc Biomater 91 (2009): 296-304.

Google Scholar, Crossref, Indexed at

5. Choi, Nak Won, Mario Cabodi, Brittany Held and Jason P. Gleghorn, et al. "Microfluidic scaffolds for tissue engineering." Nat Mater 6 (2007): 908-915.

Google Scholar, Crossref, Indexed at

6. Vunjak-Novakovic, Gordana, Kacey Ronaldson-Bouchard and Milica Radisic. "Organs-on-a-chip models for biological research." Cell 184 (2021): 4597-4611.

Google Scholar, Crossref, Indexed at